Organoids Market Size

Organoids Market Analysis

The Organoids Market is projected to register a CAGR of 17.1% during the forecast period.
The COVID-19 pandemic had a significant impact on the organoids market. The increasing number of research and development activities for the introduction of the COVID-19 vaccine within a very limited time resulted in the higher adoption of organoids during the pandemic. The resemblance with actual organs, cell tropism, cell viability, and others are some of the key factors for the significant adoption of organoids during drug development at the time of the pandemic. For instance, an article published by the National Center for Biotechnology Information (NCBI) in February 2022, reported that organoids offered a significant pace in the research of COVID-19 by offering proper cellular heterogeneity, viral susceptibility, and appropriate host cell responses. Additionally, specific organoids were reported to be effective while identifying the treatment option for COVID-19. For instance, an article published by Springer Nature Limited in May 2021, reported that lung organoids had shown promising results while detecting the treatment options for the SARS-COV-2 virus during the pandemic.

Moreover, a research journal published by Springer Nature Limited in April 2022, reported that human pluripotent stem cell-derived airway organoids have shown certain specific characteristics of the SARS-COV-2 virus as well showed effectiveness while evaluating the options to limit the spread of the virus. This results in the increased use of organoids in the research field during the pandemic and fosters the market's growth. However, in the post-pandemic situation, the research studies and clinical trials increased significantly involving organoids. For instance, according to ClinicalTrials.gov, a total of 47 studies were reported involving organoids from 1st March 2021 till 3rd January 2023. Also, an article published by MDPI in June 2022, titled '3D Human Organoids: The Next 'Viral' Model for the Molecular Basis of Infectious Diseases,' reported that organoids were proven to be efficacious in the research of a number of disorders, including COVID-19, HIV, Hepatitis B, Hepatitis C among others and gained its traction in the research of infectious disease in the post-pandemic situation. The above-mentioned factors are anticipated to contribute to the further growth of the market during the forecast period.
There are certain factors that are driving the market growth, including the rising prevalence of chronic diseases, the rising number of research on drug development involving organoids, and technological advancements in the development of organoids. The prevalence of chronic diseases, including cardiovascular disease, chronic kidney disease, and cancer, among others, is increasing globally. For instance, according to an article by the National Health Service (NHS) in May 2021, it was reported that an estimated 1.4 million people in the United Kingdom were suffering from atrial fibrillation in 2021. Additionally, according to a research article published by the Annals of Cancer Epidemiology in 2021, an estimated 235,760 new lung cancer cases were diagnosed in the United States in 2021. This rising number of patients suffering from a number of chronic diseases is increasing the healthcare burden and, alternatively, increasing the research and development initiatives for the introduction of novel drugs to be used in these chronic diseases. Additionally, owing to a better understanding of the disease condition and the effect of drugs on the actual organs, the adoption of organoid models is increasing for R&D purposes. According to ClinicalTrial.gov, a study titled 'Intestinal Organoids (BIOÏDES)' started in September 2022 in France was aimed to develop a bio-collection of organoids from digestive biopsies with associated health data prior to testing them with potential therapeutic molecules for gastrointestinal disorders.
Furthermore, a number of rising initiatives in pharmaceutical research and development were observed by the major players for the development of organoids and the application of organoids to different indications, such as lung cancer, genetic abnormalities, chronic kidney disease, cardiovascular disorders, and colon cancer, among others. These initiatives are also fueling the demand for organoids in the research field. For instance, according to ClinicalTrials.gov, a total of 79 clinical studies are there for organoids till 31st December 2022. Apart from that, the latest technological advancements in the development of organoids models were further improving the outcomes of organoids in pharmaceutical research. For instance, in October 2022, AIM Biotech Pte. Ltd. introduced organiX System. This system is capable of adding vascularization and immune competence to organoids which can improve the shelf life of organoids during the research procedure.
Thus, the above-mentioned factors are attributed to the growing demand and adoption of organoids in the pharmaceutical research field and have been instrumental in the market's growth. However, certain clinical disadvantages, including functional disparities between the organoids and actual organs, are limiting the adoption rate of organoids during the study period.